- Report
- February 2018
- 108 Pages
Global
From €4109EUR$4,250USD£3,531GBP
- Report
- February 2021
- 50 Pages
Global
From €3142EUR$3,250USD£2,700GBP
- Report
- January 2019
- 18 Pages
Global
From €9667EUR$10,000USD£8,309GBP
- Report
- January 2019
- 17 Pages
Global
From €9667EUR$10,000USD£8,309GBP
- Drug Pipelines
- January 2019
- 510 Pages
Global
From €21268EUR$22,000USD£18,280GBP
- Report
- May 2021
- 41 Pages
Global
€1274EUR$1,318USD£1,095GBP
- Report
- June 2019
- 147 Pages
Global
From €10629EUR$10,995USD£9,136GBP
The Aliqopa market is a subset of the larger lymphoma drug market, focusing on the development and commercialization of drugs for the treatment of B-cell non-Hodgkin lymphoma (NHL). Aliqopa is a monoclonal antibody that targets the CD20 antigen on B-cells, and is used in combination with chemotherapy to treat NHL. The Aliqopa market is characterized by a high degree of competition, with several companies developing and marketing similar drugs. The market is also characterized by a high degree of innovation, with companies developing new drugs and formulations to improve efficacy and safety.
Companies in the Aliqopa market include AbbVie, AstraZeneca, Bristol-Myers Squibb, Genentech, Janssen, Merck, Novartis, and Pfizer. Show Less Read more
